
Drugging the undruggable.
Founded: 2017
Headquarters: Santa Cruz, California
Employee count: 52
Focus: AI-enhanced design of macrocyclic peptide therapeutics for undruggable targets
Latest funding: Series A (Dec 19, 2023)
Therapeutics for undruggable targets (macrocyclic peptides)
2017
Biotechnology
Reported as the latest round on Dec 19, 2023; company has three funding rounds per available profiles.
“Company has multiple institutional backers including Artis Ventures and Merck Global Health Innovation Fund; Crunchbase lists 14 investors.”